🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice...
Status
Completed
Location
University of California at Los Angeles Dept. of Hematology Clinic
Start Date
2007-07-31
Trial ID
NCT00471497
The purpose of this study is to determine the survival, disease response, a...
Status
Completed
Location
The Rebecca and John Moores UCSD Cancer Center
Start Date
2010-04-21
Trial ID
NCT01140568
Treatments Being Tested
Patients with acute lymphoblastic leukemia and positivity for the breakpoin...
Status
Terminated
Location
Multiple Locations
Start Date
2009-05
Trial ID
NCT00905398
Treatments Being Tested
The extension study followed the core study CAMN107ECN02 (NCT01275196). whi...
Status
Completed
Location
Novartis Investigative Site
Start Date
2014-07-17
Trial ID
NCT02272777
In patients who are receiving nilotinib, nilotinib plasma levels will be me...
Status
Completed
Location
Asan Medical Center
Start Date
2009-01
Trial ID
NCT00976612
Treatments Being Tested
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some o...
Status
Completed
Location
Daegu Fatima Hospital
Start Date
2009-01
Trial ID
NCT00844298
Treatments Being Tested
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+...
Status
Completed
Location
Georgia Regents University
Start Date
2018-11-22
Trial ID
NCT03578367
Treatments Being Tested
The purpose of this Pilot Study is to determine if NF1 patients with plexif...
Status
Completed
Location
Riley Hospital for Children
Start Date
2011-01
Trial ID
NCT01275586
Treatments Being Tested
This is a phase 1 dose-escalation study of nilotinib in combination with fi...
Status
Recruiting
Location
University of Iowa
Start Date
2022-06-01
Trial ID
NCT04903119
whether Nilotinib at the two sequential dosage forms will induce quicker an...
Status
Terminated
Location
National Guard Hospital
Start Date
2013-03
Trial ID
NCT02086487
Treatments Being Tested